Capstone Investment Advisors LLC Acquires Shares of 12,805 Treace Medical Concepts, Inc. (NASDAQ:TMCI)

Capstone Investment Advisors LLC bought a new stake in shares of Treace Medical Concepts, Inc. (NASDAQ:TMCIFree Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 12,805 shares of the company’s stock, valued at approximately $163,000.

Other hedge funds have also recently modified their holdings of the company. Quest Partners LLC purchased a new position in Treace Medical Concepts during the 4th quarter worth $68,000. Trexquant Investment LP bought a new position in shares of Treace Medical Concepts during the 4th quarter worth $132,000. Norges Bank purchased a new position in shares of Treace Medical Concepts during the fourth quarter valued at $8,725,000. Roubaix Capital LLC bought a new stake in shares of Treace Medical Concepts in the fourth quarter valued at about $1,566,000. Finally, TimesSquare Capital Management LLC lifted its stake in Treace Medical Concepts by 22.0% in the fourth quarter. TimesSquare Capital Management LLC now owns 1,749,120 shares of the company’s stock worth $22,301,000 after acquiring an additional 315,691 shares during the period. Institutional investors own 84.08% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. Morgan Stanley lowered shares of Treace Medical Concepts from an “overweight” rating to an “equal weight” rating and reduced their price target for the company from $15.00 to $5.50 in a report on Wednesday, May 8th. Stifel Nicolaus downgraded shares of Treace Medical Concepts from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $15.00 to $6.00 in a research note on Wednesday, May 8th. Truist Financial cut Treace Medical Concepts from a “buy” rating to a “hold” rating and dropped their target price for the company from $17.00 to $7.00 in a research report on Wednesday, May 8th. UBS Group lowered Treace Medical Concepts from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $16.00 to $6.50 in a research report on Thursday, May 16th. Finally, BTIG Research downgraded Treace Medical Concepts from a “buy” rating to a “neutral” rating in a research report on Wednesday, May 8th. Seven investment analysts have rated the stock with a hold rating, Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $12.21.

Get Our Latest Stock Analysis on Treace Medical Concepts

Treace Medical Concepts Trading Down 0.9 %

Shares of NASDAQ:TMCI opened at $5.43 on Wednesday. The company has a debt-to-equity ratio of 0.42, a current ratio of 3.98 and a quick ratio of 3.22. The firm has a market capitalization of $336.71 million, a P/E ratio of -6.17 and a beta of 0.18. The business’s 50-day moving average is $9.12 and its 200 day moving average is $11.16. Treace Medical Concepts, Inc. has a 1 year low of $3.92 and a 1 year high of $26.63.

Treace Medical Concepts (NASDAQ:TMCIGet Free Report) last released its earnings results on Tuesday, May 7th. The company reported ($0.30) earnings per share for the quarter, hitting the consensus estimate of ($0.30). Treace Medical Concepts had a negative net margin of 27.93% and a negative return on equity of 39.66%. The company had revenue of $51.11 million for the quarter, compared to the consensus estimate of $49.07 million. During the same quarter in the previous year, the firm earned ($0.23) EPS. Treace Medical Concepts’s revenue was up 21.1% compared to the same quarter last year. On average, research analysts predict that Treace Medical Concepts, Inc. will post -0.87 earnings per share for the current fiscal year.

Insider Activity at Treace Medical Concepts

In other news, Director James T. Treace purchased 25,000 shares of the stock in a transaction on Friday, May 31st. The stock was bought at an average price of $6.05 per share, with a total value of $151,250.00. Following the transaction, the director now owns 1,139,441 shares in the company, valued at approximately $6,893,618.05. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Treace Medical Concepts news, Director James T. Treace acquired 50,000 shares of the company’s stock in a transaction dated Tuesday, May 28th. The shares were acquired at an average cost of $5.07 per share, with a total value of $253,500.00. Following the acquisition, the director now directly owns 1,089,441 shares of the company’s stock, valued at $5,523,465.87. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director James T. Treace bought 25,000 shares of Treace Medical Concepts stock in a transaction that occurred on Friday, May 31st. The shares were acquired at an average cost of $6.05 per share, with a total value of $151,250.00. Following the acquisition, the director now owns 1,139,441 shares of the company’s stock, valued at $6,893,618.05. The disclosure for this purchase can be found here. Insiders have bought a total of 548,902 shares of company stock valued at $2,665,822 in the last ninety days. Company insiders own 24.43% of the company’s stock.

Treace Medical Concepts Company Profile

(Free Report)

Treace Medical Concepts, Inc, a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity.

Recommended Stories

Institutional Ownership by Quarter for Treace Medical Concepts (NASDAQ:TMCI)

Receive News & Ratings for Treace Medical Concepts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Treace Medical Concepts and related companies with MarketBeat.com's FREE daily email newsletter.